刘丽宏教授团队成员包括从事药理学、代谢组学、药物基因组学等方面研究的科研人员，其中具有博士学位的研究人员17人、硕士学位的研究人员8人，具有高级职称17人。研究团队近年研究方向为：1.基于多组学技术的精准药物研发及评价。包括药物精准设计、类器官的药物肝毒性评价和肿瘤药敏预测以及利用BXD重组近交系小鼠进行药物评价及个体化用药研究等。2. 基于代谢组学的疾病生物标志物发现研究。包括利用代谢组学技术探索糖尿病合并心梗的机制以及生物标志物在筛选治疗或缓解代谢综合征药物中的应用等。刘丽宏教授团队以第一/通讯作者在Advanced Materials（IF 25.809）、The BMJ（IF 39.890）等期刊上发表论文200余篇，获得中国国家发明专利授权30余项。

1.国家自然科学基金项目：木通皂苷D上调肠道拟杆菌增强肠源EPA合成治疗动脉粥样硬化的机制研究 2025年1月-2028年12月，【82474324】，资助48万元，在研，主持。

2.北京市自然科学基金-北京经济技术开发区创新联合基金项目：肠道拟杆菌及 δ5-去饱和酶作为合成 EPA 治疗动脉粥样硬化靶点及木通皂苷 D 作用研究 2024年10月 - 2027年9月，【L248089】，资助30万元，在研，主持。

3.北京市科技计划：治疗代谢综合征中药 1 类新药ASD 研发 2022年11月-2026年11月，【Z221100007922021】，资助700万元，在研，主持。

4.中国医学科学院医学与健康科技创新工程：临床试验及临床试验机构评价体系构建与应用研究 2021年10月-2025年12月，【2021-I2M-I-045】，资助2400万元，在研，主持。

慢病新药创制关键桥接技术北京市重点实验室主任

呼吸和共病全国重点实验室-创新药物研发方向负责人

中医药管理局高水平重点学科（中西医结合临床）学术带头人 

一、SCI论文

1. Hu, T., An, Z., Li, H., Liu, Y., Xia, L., Qiu, L., Yao, A., Ma, L., & Liu, L. (2022). UHPLC-MS/MS-Based Metabolomics and Clinical Phenotypes Analysis Reveal Broad-Scale Perturbations in Early Pregnancy Related to Gestational Diabetes Mellitus. Disease markers, 2022, 4231031. IF=3.464/Q3.

2. Cong, L., Wan, Z., Li, P., Liu, D., He, J., An, Z., & Liu, L. (2022). Metabolic, genetic, and pharmacokinetic parameters for the prediction of olanzapine efficacy. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 177, 106277. IF=5.112/Q2.

3. An, Z., Zhao, R., Han, F., Sun, Y., Liu, Y., & Liu, L. (2022). Potential Serum Biomarkers Associated with Premature Rupture of Fetal Membranes in the First Trimester. Frontiers in pharmacology, 13, 915935. IF=5.988/Q2.

4. Li, P., Cong, Y., Zhang, W., Wang, L., Ren, L., Li, X., Yang, S., Zhang, Z., Li, G., & Liu, L. (2022). Simultaneous quantification of apolipoproteins A-I, E, and J in human plasma by LC-MS/MS for clinical application to diabetes mellitus complicated with cardiovascular disease. RSC advances, 12(26), 16763–16771. IF= 4.036/Q3.

5. An, Z., Sun, Y., Shi, C., & Liu, L. (2022). Metabonomic and transcriptomic analyses of Tripterygium glycosides tablet-induced hepatotoxicity in rats. Drug and chemical toxicology, 1–15. Advance online publication. IF= 2.597/Q4.

6. Sun, Y., Cong, L., Yang, S., Zhao, R., An, Z., & Liu, L. (2022). Moxifloxacin Induced Liver Injury by Causing Lachnospiraceae Deficiency and Interfering with Butyric Acid Production through Gut-Liver Axis. Disease markers, 2022, 9302733. IF=3.464/Q3.

7. Li, P., Wu, H., Zhao, Z., Du, P., Xu, H., Liu, H., Zhou, Y., Yu, W., Li, H., & Liu, L. (2022). Simultaneous Quantitation of Clevidipine and Its Active Metabolite H152/81 in Human Whole Blood by LC-MS/MS: Application to Bioequivalence Study. Frontiers in chemistry, 10, 861952.IF= 5.545/Q2.

8. Du, P., Liu, L., Hu, T., & An, Z. (2022). Integrative Analysis of Pharmacokinetic and Metabolomic Profiles for Predicting Metabolic Phenotype and Drug Exposure Caused by Sotorasib in Rats. Frontiers in oncology, 12, 778035.IF= 5.738/Q2.

9. Liang, Y., Zhu, Y., Zhang, Y., Chen, Z., Li, B., Liu, A., & Liu, L. (2022). Clinical Observation and Pharmacoeconomic Evaluations of Original Research Drug and Generic Drug Bortezomib in the Treatment of Multiple Myeloma. Journal of healthcare engineering, 2022, 5201354.IF= 3.822/Q4.

10. Zhang, X., An, Z., Lv, Y., Li, G., Liu, L., & Li, P. (2022). Simultaneous Determination of RDX and HMX in Rat Plasma by LC-MS/MS and its Applications. Frontiers in chemistry, 10, 808226. IF= 5.545/Q2.

11. Du, P., Xuan, L., Hu, T., An, Z., & Liu, L. (2022). Serum Eicosanoids Metabolomics Profile in a Mouse Model of Renal Cell Carcinoma: Predicting the Antitumor Efficacy of Anlotinib. Frontiers in immunology, 13, 824607. IF= 8.786/Q2.

12. Sun, X., Ma, Z., Guo, Q., Zhao, Z., & Liu, L. (2022). Ibrutinib-related skin cancer: A pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System. European journal of cancer (Oxford, England : 1990), 160, 277–278.IF10.002/Q1.

13. Tang B, Wang X, Wang X, Liu L, Ma Z. Genotype-Guided Antiplatelet Therapy Versus Standard Therapy for Patients with Coronary Artery Disease: An Updated Systematic Review and Meta-Analysis. J Pharm Pharm Sci. 2022;25:9-23.IF=3.337/Q4

14. Zhou, H., Liu, L., Sun, X., Wang, H., Yu, X., Su, Y., You, Z., & An, Z. (2021). The impact of pharmacist intervention on prophylactic antibiotics use in orthopedic surgery at a hospital in China. Medicine, 100(52), e28458.IF= 1.817/Q4.

15. Ying Wang, Zhikang Ye, Long Ge, Reed A Siemieniuk, Xin Wang, Yingkai Wang, Liangying Hou, Zhuo Ma, Thomas Agoritsas, Per Olav Vandvik, Anders Perner, Morten H Møller, Gordon H Guyatt, Lihong Liu*. Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: systematic review and network meta-analysis. BMJ. 2020, 368:l6744. IF=30.313.

16. Zhikang Ye, Annika Reintam Blaser, Lyubov Lytvyn, Ying Wang, Gordon H. Guyatt, J. Stephen Mikita, Jamie Roberts, Thomas Agoritsas, Sonja Bertschy, Filippo Boroli, Julie Camsooksai, Bin Du, Anja Fog Heen, Jianyou Lu, José M. Mella, Per Olav Vandvik, Robert Wise, Yue Zheng, Lihong Liu*, Reed A.C. Siemieniuk. Gastrointestinal bleeding prophylaxis for critically ill patients: a clinical practice guideline. BMJ. 2020, 368:l6722. IF=30.313.

17. Wang X, Wang S, Yu X, Ma Z, Wang H, Yang J, Liu L. Impact of pharmacist-led medication therapy management in ambulatory elderly patients with chronic diseases. Br J Clin Pharmacol. 2021 Jul;87(7):2937-2944. IF=4.335

18. Sun X, Wang X, Zhang J, Zhao Z, Feng X, Liu L, Ma Z. Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review. Breast. 2021 Dec;60:26-34. doi: 10.1016/j.breast.2021.08.009. Epub 2021 Aug 21. PMID: 34455227; PMCID: PMC8399371. IF=4.380

19. Lu W, Guo Q, Ma Z, Liu L, Zhao Z. Lenvatinib and osteonecrosis of the jaw: A pharmacovigilance study. Eur J Cancer. 2021 Jun;150:211-213. doi: 10.1016/j.ejca.2021.03.046. Epub 2021 May 3. IF=7.275

20. Ma Z, Sun X, Zhao Z, Lu W, Guo Q, Wang S, You J, Zhang Y, Liu L. Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database. Gynecol Oncol. 2021 Aug;162(2):496-505. IF=4.623

21. Du P, Wang GY, Zhao R, An ZL, Liu LH. Eicosanoid Metabolomic Profile of Remdesivir Treatment in Rat Plasma by High-Performance Liquid Chromatography Mass Spectrometry. Front Pharmacol. 2021 Sep 29;12:747450. doi: 10.3389/fphar.2021.747450. PMID: 34658883; PMCID: PMC8511316. IF=5.811

22. Zhao R, An Z, Sun Y, Xia L, Qiu L, Yao A, Liu Y, Liu L. Metabolic profiling in early pregnancy and associated factors of folate supplementation: A cross-sectional study. Clin Nutr. 2021 Sep;40(9):5053-5061. doi: 10.1016/j.clnu.2021.01.012. Epub 2021 Jan 23. PMID: 34455263. IF=7.325

23. Yang S, Hu T, Liu H, Lv YL, Zhang W, Li H, Xuan L, Gong LL, Liu LH. Akebia saponin D ameliorates metabolic syndrome (MetS) via remodeling gut microbiota and attenuating intestinal barrier injury. Biomed Pharmacother. 2021 Jun;138:111441. IF=6.529

24. An Z, Shi C, Li P, Liu L. Stability of amino acids and related amines in human serum under different preprocessing and pre-storage conditions based on iTRAQ®-LC-MS/MS. Biol Open. 2021 Feb 26;10(2):bio055020. IF=2.029

25. Yang H, Sun Y, Yu X, Hu X, Wang W, Zhang X, Liu L. Clinical Impact of the Adaptation of Initial Tacrolimus Dosing to the CYP3A5 Genotype After Kidney Transplantation: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin Pharmacokinet. 2021 Jul;60(7):877-885. IF=6.447

26. Li P, Peng J, Li Y, Gong L, Lv Y, Liu H, Zhang T, Yang S, Liu H, Li J, Liu L. Pharmacokinetics, Bioavailability, Excretion and Metabolism Studies of Akebia Saponin D in Rats: Causes of the Ultra-Low Oral Bioavailability and Metabolic Pathway. Front Pharmacol. 2021 Apr 15;12:621003. IF=4.225

27. Li-li Gong*, Song Yang, Wen Zhang, Fei-fei Han, Ya-li Lv, Ling-ling Xuan, He Liu, Li-hong Liu*. Discovery of metabolite profiles of metabolic syndrome using untargeted and targeted LC–MS based lipidomics approach. Journal of Pharmaceutical and Biomedical Analysis. 2020. 177: 112848. IF=3.209

28. Lingling Xuan, Lulu Ren, Feifei Han, Lili Gong, Zirui Wan, Song Yang, He Liu, Yali Lv*, Lihong Liu*. Cytomegalovirus Infection Exacerbates Experimental Colitis by Promoting IL-23 Production. Inflammation. 2020, 43(1):326-335. IF=3.212

29. Zhuo Ma#, ZhiXia Zhao#, ShuSen Sun, YiFan Li, ZhuoLing An, Yan Yan, LiHong Liu*. Impact of Chief Pharmacist System on drug expenditures and rational drug use. International Journal of Clinical Pharmacy. 2020, 42(1):167-173. IF=1.616

30. Hui Yang, Lizhen Pang, Xiaopeng Hu, Wei Wang, Bifang Xu, Xiaodong Zhang, Lihong Liu*. The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: a systematic review and meta-analysis. J Clin Pharm Ther. 2020, 45:1058-1065. IF=1.833

31. Xin Wang, Jing Yang, Xiaojia Yu, Zihui Wang, Huaguang Wang, Lihong Liu*. Characterization of drug-related problems and associated factors in ambulatory patients in China. J Clin Pharm Ther. 2020, doi: 10.1111/jcpt.13161. IF=1.833

32. Xin Wang#, Hui Yang#, Xiaopeng Hu, Wei Wang, Xiaojia Yu, Shihui Wang, Xiaodong Zhang*, Lihong Liu*. Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. J Oncol Pharm Pract. 2020, doi: 10.1177/1078155220929414. IF=1.85

33. Xin Wang, Shihui Wang, Jing Yang, Xiaojia Yu, Lihong Liu*. Genotype-guided antiplatelet therapy compared with standard therapy for patients with acute coronary syndromes or undergoing percutaneous coronary intervention: A systematic review and meta-analysis. Thromb Res. 2020, 193:130-138. IF=2.869

34. Yahui Yu#, Hui Yang#, Xiaojia Yu, Xiaopeng Hu, Wei Wang, Xiaoyong Yang, Hang Liu, Liang Ren, Xiaodong Zhang, Lihong Liu*, Xin Feng*. Critical appraisal of the quality and content of clinical practice guidelines for pneumocystis jiroveci pneumonia (PJP) prophylaxis using the AGREE II instrument. Journal of Clinical Pharmacy and Therapeutics. 2020, doi: 10.1111/jcpt.13213. IF=1.833

35. Hui Yang#, Yahui Yu#, Xiaopeng Hu, Wei Wang, Xiaoyong Yang, Hang Liu, Liang Ren, Xiaodong Zhang, Xin Feng, Lihong Liu*. The Association Between the Overall Risk of Prostate Cancer and Calcium Channel Blockers use: A Systematic Review and Meta-Analysis. Clinical Therapeutics. 2020, doi: 10.1016/j.clinthera.2020.06.021. IF=3.119

36. Lingling Xuan, Feifei Han, Lili Gong, Yali Lv, Zirui Wan, He Liu, Lulu Ren, Song Yang, Wen Zhang, Ting Li, Chunting Tan, Yuan Sun, Benshan Xu, Lihong Liu*. Ceramide Induces MMP-9 Expression Through JAK2/STAT3 Pathway in Airway Epithelium. Lipids Health Dis. 2020, 19(1):196. IF=2.906

37. Lifang Guo#, Shumin Wang#, Zirui Wan#, Siyang Ni, Benshan Xu, Xiuli Zhao*，Lihong Liu*. Influence of CYP2D6*5 and *10 polymorphism on the pharmacokinetics of nebivolol in healthy Chinese subjects. Journal of Clinical Pharmacy and Therapeutics. 2020, doi: 10.1111/jcpt.13155. IF=1.833

38. Lulu Ren, Lingling Xuan, Feifei Han, Jie Zhang, Lili Gong, Yali Lv, Wen Zhang, Song Yang, Benshan Xu, Yan Yan, Lifang Guo, He Liu, Zirui Wan*, Lihong Liu*. Vitamin D supplementation rescues simvastatin induced myopathy in mice via improving mitochondrial cristae shape. Toxicology and Applied Pharmacology. 2020, 401:115076. IF=3.347

39. Dan Liu#, Zhuoling An#, Pengfei Li, Yanhua Chen, Ruiping Zhang, Lihong Liu*, Jiuming He*, Zeper Abliz. A targeted neurotransmitter quantification and nontargeted metabolic profiling method for pharmacometabolomics analysis of olanzapine by using UPLC-HRMS. RSC Advances. 2020, 10:18305-18314. IF=3.119

40. Zirui Wan#*, Lifang Guo#, Pengfei Li#, Zhixia Zhao, Benshan Xu, Lulu Ren, Yan Yan, He Liu, Yiwen Zhang, Lihong Liu*. Determinants of Gefitinib Pharmacokinetics in Healthy Chinese Male Subjects: A Pharmacogenomic Study of Cytochrome p450 Enzymes and Transporters. journal of clinical pharmacy and therapeutics. 2020, doi: 10.1111/jcpt.13168. IF=1.833

41. Ping Du, Ting Hu, Zhuoling An, Pengfei Li, Lihong Liu*. In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. Cancer Science. 2020, 11(6):1887-1898. IF=4.966

42. Ping Du, Ting Hu, Zhuoling An, Pengfei Li, Lihong Liu*. Simultaneous quantitative determination of arachidonic acid and cascade metabolites in rat serum by UPLC-MS/MS: application for longitudinal metabolomics of anlotinib. Analyst. 2020, 145(14):4972-4981. IF=3.978

43. Ping Du, Pengfei Li, Hongchuan Liu, Rui Zhao, Zhixia Zhao, Weiyue Yu, Xin Zhou, Lihong Liu*. Open-Label, Randomized, Single-Dose, 2-Period, 2-Sequence Crossover, Comparative Pharmacokinetic Study to Evaluate Bioequivalence of 2 Oral Formulations of Olanzapine Under Fasting and Fed Conditions. Clinical pharmacology in drug development. 2020, 9(5):621-628. IF=1.903

44. Zhuo Ma, YaLan Tong, Caixai Zhang, Lihong Liu*. Potentially inappropriate medications and potentially prescribing omissions in Chinese older patients: Comparison of two versions of STOPP/START. J Clin Pharm Ther. 2020, doi: 10.1111/jcpt.13237. IF=1.833

45. Fei-fei Han#, Hua Fan#, Lu-lu Ren, Hua-guang Wang, Chunlin Wang, Ma Xu*, Li-hong Liu*, Qiang He*, Chang-long Guo*. Profiling the pattern of human TRB/IGH‐CDR3 repertoire in liver transplantation patients via high‐throughput sequencing analysis. Scandinavian Journal of Immunology. 2020, 9(2):e12912. IF=2.717

46. Ya-li Lv, Yangjie Jia, Zirui Wan, Zhuo-ling An, Song Yang, Fei-fei Han, Li-li Gong, Ling-ling Xuan, Lu-lu Ren, Wen Zhang, He Liu*, Li-hong Liu*. Curcumin inhibits the formation of atherosclerosis in ApoE-/- mice by suppressing human cytomegalovirus activity in endothelial cells. Life Sciences. 2020, 257:117658. IF=3.647

47. Ting Hu#, Zhuoling An#, Yongkun Sun, Xunqiang Wang, Ping Du, Pengfei Li, Yihebali Chi*, Lihong Liu*. Longitudinal Pharmacometabonomics for Predicting Malignant Tumor Patient Responses to Anlotinib Therapy: Phenotype, Efficacy and Toxicity. Frontiers in Oncology. 2020, doi: 10.3389/fonc.2020.548300. IF=4.848

48. Fei-fei Han*, Lu-lu Ren, Ling-ling Xuan, Ya-li LV, He Liu, Li-li Gong, Zhuo-ling An, Li-hong Liu*. HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer. Cancer Chemotherapy and Pharmacology. 2020, 1-10. IF=2.967

49. Song Yang, Wen Zhang, Ling-ling Xuan, Fei-fei Han, Ya-li Lv, Zi-rui Wan, He Liu, Lu-lu Ren, Li-li Gong*, Li-hong Liu*. Akebia Saponin D inhibits the formation of atherosclerosis in ApoE-/- mice by attenuating oxidative stress-induced apoptosis in endothelial cells. Atherosclerosis. 2019, 285: 23-30. IF=3.919

50. Li-li Gong, Song Yang, He Liu, Wen Zhang, Lu-lu Ren, Fei-fei Han, Ya-li Lv, Zi-Rui Wan, Li-hong Liu*. Anti-nociceptive and anti-inflammatory potentials of Akebia saponin D. Eur J Pharmacol. 2019, 845: 85-90. IF=3.263

51. Guo L, Wan Z, Xu B, Ren L, Liu H, Song N*, Liu L*. Blockade of angiogenin by thalidomide inhibits the tumorigenesis of murine hemangioendothelioma. Fundam Clin Pharmacol. 2019, doi: 10.1111/fcp.12478. IF=2.754

52. Lifang Guo*, Benshan Xu, Daifu Zhou, Guodong Chang, Yan Fu, Lihong Liu*, Yongzhang Luo*. Biophysical and biological characterization of PEGylated recombinant human endostatin. Clin Exp Pharmacol Physiol. 2019,46(10):920-927. IF=2.456

53. Lifang Guo*, Zuogang Li , Benshan Xu , Min Yu, Yan Fu, Lihong Liu*, Junzhi Wang*, Yongzhang Luo*. Pharmacokinetics of PEGylated Recombinant Human Endostatin in Rhesus Monkeys. Life Sci. 2019,238:116867. IF=3.647

54. Lulu Ren, Feifei Han, Lingling Xuan, Yali Lv, Lili Gong, Yan Yan, Zirui Wan, Lifang Guo, He Liu, Benshan Xu, Yuan Sun,Song Yang, Lihong Liu*. Clusterin ameliorates endothelial dysfunction in diabetes by suppressing mitochondrial fragmentation. Free Radical Biology and Medicine. 2019,145:357-373. IF=6.17

55. Wen Zhang, Lili Gong, Song Yang, Yali Lv, Feifei Han, He Liu, Lihong Liu*. Lipidomics Profile Changes of Type 2 Diabetes Mellitus with Acute Myocardial Infarction. Disease Markers. 2019, 2019: doi:10.1155/2019/7614715. IF=2.738

56. Jiaming Fan#, Pengfei Li#, He Liu, Rui Zhao, Zhixia Zhao, Ping Du, Lihong Liu*. Optimized liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry method for the quantitation of paraquat in plasma: application to a toxicokinetic study. Analytical methods. 2019,11(21):2756-2762. IF=2.596

57. Ping Du, Pengfei Li, Rui Zhao, Hongchuan Liu, Lihong Liu*. Optimized UPLC-MS/MS method for the quantitation of olanzapine in human plasma: application to a bioequivalence study. Bioanalysis. 2019,11(13):1291-1302. IF=2.371

58. Ping Du, Yin Guan, Zhuoling An, Pengfei Li, Lihong Liu*. A selective and robust UPLC-MS/MS method for simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to pharmacokinetic study. Analyst. 2019, 144(18):5462-5471. IF=3.978

59. Zhuoling An, Ting Hu, Yali Lv, Pengfei Li, Lihong Liu*. Targeted amino acid analysis based on iTRAQ-LC-MS/MS for discovering potential hepatotoxicity biomarkers. Journal of Pharmaceutical and Biomedical Analysis. 2019, 178:112812. IF=3.209

60. Ting Hu#, Zhuoling An#, Chen Shi, Pengfei Li, Lihong Liu*. A Sensitive and Efficient Method for Simultaneous Profiling of Bile Acids and Fatty Acids by UPLC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 2019, 178:112815. IF=3.209

61. Huaguang Wang, Han Wang, Xiaojia Yu, Hong Zhou, Boyu Li, Gang Chen, Zhikang Ye, Ying Wang, Xiangli Cui, Yunying Zheng, Rui Zhao, Hui Yang, Zihui Wang, Peng Wang, Chunxia Yang, Lihong Liu*. Impact of antimicrobial stewardship managed by clinical pharmacists on antibiotic use and drug resistance in a Chinese hospital, 2010–2016: a retrospective observational study. BMJ Open. 2019, 9(8):e026072. IF=2.496

二、专利

1. 用于预测胎膜早破的生物标记物和方法（授权202110025863.4）

2. 检测代谢物标志物在制备多发性骨髓瘤诊断工具中的应用（授权202010843788.8）

3. 快速诊断多发性骨髓瘤的代谢标志物及应用（授权202210777997.6）

4. HMG-CoA还原酶抑制剂-维D的药物组合物及用途（授权CN202011407443.4）

5. 糖尿病合并心梗代谢标志物、检测试剂及试剂盒（授权CN202011336940.X）

6. 莫西沙星相关肝损伤的生物标志物、试剂盒及应用（授权CN202011280477.1）

7. 超高效液相色谱串联质谱测定血浆中AMG510浓度的方法（授权CN202010962969.2）

8. 他汀和维生素D组合物及其制备方法与用途（授权CN202010697511.9）

9. 基于双衍生化技术的脂肪酸LC-MS/MS分析方法（授权CN202010347538.5） 

10. 木通皂苷D-有机酸的药物共晶体及其用途（授权CN202010123135.2） 

11. 治疗痰热壅症的成人儿童共用中药制剂及其制备方法和应用（授权CN201910959521.2） 

12. 治疗风湿性类风湿性关节炎的组合物及其制备方法和应用（授权CN201910927101.6） 

13. 高效液相色谱串联质谱测定血浆中奥氮平浓度的方法（授权CN201910186286.X） 

14. 包含生物小分子及基因的肝损伤生物标志物、方法及应用（授权CN201810390304.1） 

15. 用于早期发现与预警肝损伤的生物标志物、方法及应用（授权CN201810390293.7） 

16. 生物标志物在筛选治疗或缓解代谢综合征的药物中的用途（授权CN201710049441.4） 

17. 生物标记用于制备试剂盒的用途（授权CN201710042371.X） 

18. 一种应用于治疗代谢综合征的药物（授权CN201410256108.7） 

19. 姜黄素及其衍生物在制备治疗人巨细胞病毒感染药物中的应用（授权CN201010544830.2）

20. 醛糖还原酶阻化剂在制备治疗肺癌药物的应用（授权CN202211177580.2）

21. 一种木通皂苷D原料药的制备方法及其应用（授权CN202210648663.9）

22. 一种高灵敏检测PBMC中他克莫司浓度的方法（授权CN202110949046.8）

23. 一种人外周血单个核细胞膜表面转运体的检测方法及应用（授权CN202111255448.4）

24. 一种试剂盒，用于实现鞘内阿片类镇痛药使用剂量的预测方法（授权CN202211487301.2）

25. 用于鞘内阿片类镇痛药的剂量预测方法及装置（授权CN202211205118.9）

26. 评估ARB类药物疗效的多态性位点组合、试剂盒及检测系统（授权CN116287190B）

27. 用于检测环孢素A肾毒性相关标志物的检测试剂、试剂盒及其用途（授权CN202210832398.X）

28. 与肥胖相关疾病相关的蛋白质簇集素及其应用（授权CN202210342740.8）

29. 鞘脂代谢标志物及其分析方法和应用（授权CN202311394888.7）

30. 一种基于基因多态性及血浆细胞因子的肺移植排斥预测方法及应用（授权CN202310414262.1）

31. 预测他克莫司代谢能力的多态性位点组合、预测模型及试剂盒（授权CN202410013329.5）

32. 木通皂苷D在制备抗骨骼肌萎缩、肌病药物中的应用（授权CN202410005093.0）

33. 一种药物组合物及其在制备抗肿瘤药物中的应用（授权CN202410495593.7）

34. 一种药物组合物及其在制备抗非小细胞肺癌药物中的应用 （授权CN202411268667.X）

35. 续断皂苷类化合物及其制备方法和在制备防治脂肪肝类药物中的应用（授权CN116425821B）

三、学术奖励

 1.《氯胺酮快速抗抑郁治疗研究》 北京医学科技奖 三等奖 2020年

 2.《载脂蛋白液相色谱串联质谱法定量检测试剂盒开发及临床转发》 全国临床创新发明 三等奖 2020年

3.《治疗NAFLD的中药1类新药GXE061项目》评为2024年度北京市医药卫生科技促进中心优促计划赋能项目

四、著作

1 、感染性疾病病例评析多学科诊疗思路精粹 主编 科学技术文献出版社 2023

2、 中国总药师制度的探索与实践  主编  人民卫生出版社 2020

3 、国家药物政策与基本药物制度——管理与实践  编委  人民卫生出版社 2020

4 、药物治疗管理教学与实践手册  编委  人民卫生出版社 2018

5、 解密朝阳药学变革之路 主编  科学技术文献出版社 2018

 6、解密朝阳之临床思维构建  主编  科学技术文献出版社 2017